10.04.2013 - In a thorough comparison, Lundbeck's new antidepressant Brintellix shone brightly: On a system for rating depression patients performed better.
Danish H. Lundbeck A/S reported on positive results for the REVIVE study, a double-blind randomised study of Brintellix (vortioxetine) in adults with major depressive disorder (MDD) who changed antidepressant treatment after an inadequate response to SSRI or SNRI treatment. In this study, the objective was to compare the efficacy and tolerability of flexible dose treatment with Brintellix (10-20mg/day) versus Servier's agomelatine (25-50mg/day) in this challenging MDD patient population. "Patients with inadequate response to current SSRI or SNRI therapies represent a large proportion of patients suffering from major depression. Only a few years ago, the landmark STAR*D study1 confirmed a significant unmet medical need, as only half of patients responded to their first-line treatment, which was an SSRI," said Executive Vice President Anders Gersel Pedersen, Head of Research & Development at Lundbeck. The US-American FDA accepted an NDA from Lundbeck and its partner Takeda on Brintellix last December.
Brintellix is under investigation as a multimodal antidepressant thought to work through a combination of two complementary mechanisms of action: receptor activity modulation and reuptake inhibition. In vivo non-clinical studies have demonstrated that Brintellix modulates neuronal firing and neurotransmitter release in multiple systems, resulting in enhanced levels of serotonin, noradrenaline, dopamine, acetylcholine and histamine in specific areas of the brain. The multimodal activity profile of Brintellix is different from the profile of currently anti-depressive medicines.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.